FDA approvals hit a new high mark in 2012, with a December flurry of approvals. Orphan and fast-track drugs showed strong in the list. Randy Osborne reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Osborne, R. Fresh from the biotech pipeline—2012. Nat Biotechnol 31, 100–103 (2013). https://doi.org/10.1038/nbt.2498
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2498
This article is cited by
-
Enhancing the Buccal Mucosal Delivery of Peptide and Protein Therapeutics
Pharmaceutical Research (2015)